Iron and hepatitis C

Current Hepatitis Reports

Volumn 9, Issue 3, 2010, Pages 169-177

  Narang, Tarun K ^b   Sendi, Hossein ^b   Scobey, Martin W ^b   Bonkovsky, Herbert L ^a,b  

^a Cannon Research Center   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis; Ferroportin; Hepatitis C; Hepcidin; Iron; Oxidative stress; Reactive oxygen species

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BONE MORPHOGENETIC PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD71 ANTIGEN; DEFERASIROX; FERRITIN; FERROPORTIN; HEME OXYGENASE 1; HEPCIDIN; HFE PROTEIN; INTERLEUKIN 6; PEGINTERFERON; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; SMAD4 PROTEIN; STAT3 PROTEIN; TRANSFERRIN RECEPTOR 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FERRITIN BLOOD LEVEL; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER CELL CARCINOMA; LIVER INJURY; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; REVIEW; THALASSEMIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 77955981308     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0049-z     Document Type: Review

References (51)

1. Alla V, Bonkovsky HL: Iron in nonhemochromatotic liver disorders. Semin Liver Dis 2005, 25:461-472.
2. Bonkovsky HL, Banner BF, Rothman AL: Iron and chronic viral hepatitis. Hepatology 1997, 25:759-768. This article provides an important authoritative review, summarizing comprehensively earlier literature.
3. Scobey M, Bonkovsky H: Iron: a putative reason for genderbased differences in chronic liver disease. In Female Hepatology: Impact of Female Sex Against Progression of Liver Disease. Edited by Shimizu I. Kerala, India: Research Signpost; 2009:97-128. This reference is a recent overview and synthesis of how iron may be a key factor that accounts for gender-based differences in severity of liver disease.
4. Isom HC, McDevitt EI, Moon MS: Elevated hepatic iron: a confounding factor in chronic hepatitis C. Biochim Biophys Acta 2009, 1790:650-662.
5. Philippe MA, Ruddell RG, Ramm GA: Role of iron in hepatic fibrosis: one piece in the puzzle. World J Gastroenterol 2007, 13:4746-4754.
6. Bonkovsky HL, Naishadham D, Lambrecht RW, et al.: Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006, 131:1440-1451. This article is a report of the larger HALT-C cohort, showing associations of iron with severity of CHC and yet showing that the H63D genetic variation of HFE improved the chances of response to IFN/ribavirin.
7. Afridi HI, Kazi TG, Kazi NG, et al.: Determination of copper and iron in biological samples of viral hepatitis (A-E) female patients. Biol Trace Elem Res 2009, 129:78-87.
8. Shan Y, Lambrecht RW, Bonkovsky HL: Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis 2005, 40:834-841.
9. Guyader D, Thirouard AS, Erdtmann L, et al.: Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 2007, 46:587-595.
10. Won JE, Jeong SH, Chung JI, et al.: Hepatic iron, serum ferritin, HFE mutation, and hepatic fibrosis in chronic hepatitis C. Intervirology 2009, 52:239-246.
11. Fujita N, Sugimoto R, Urawa N, et al.: Hepatic iron accumulation is associated with disease progression and resistance to interferon/ ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007, 22:1886-1893.
12. Kohgo Y, Ikuta K, Ohtake T, et al.: Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/ insulin resistance. World J Gastroenterol 2007, 13:4699-4706.
13. Cho H, Lee HC, Jang SK, Kim YK: Iron increases translation initiation directed by internal ribosome entry site of hepatitis C virus. Virus Genes 2008, 37:154-160.
14. Hou WH, Rossi L, Shan Y, et al.: Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J Gastroenterol 2009, 15:4499-4510.
15. Lehmann E, El-Tantawy WH, Ocker M, et al.: The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology 2010, 51:398-404.
16. Furutani T, Hino K, Okuda M, et al.: Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130:2087-2098. This article is a clear demonstration of the importance of iron in development of HCC in HCV-expressing hepatocytes.
17. Fillebeen C, Muckenthaler M, Andriopoulos B, et al.: Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol 2007, 47:12-22.
18. Price L, Kowdley KV: The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol 2009, 23:822-828.
19. Drakesmith H, Prentice A: Viral infection and iron metabolism. Nat Rev Microbiol 2008, 6:541-552.
20. Peslova G, Petrak J, Kuzelova K, et al.: Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood 2009, 113:6225-6236.
21. Nemeth E, Ganz T: The role of hepcidin in iron metabolism. Acta Haematol 2009, 122:78-86. This article is a contemporary review by leaders in the study of hepcidin.
22. Fujita N, Sugimoto R, Takeo M, et al.: Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007, 13:97-104. This article provides a demonstration of low hepcidin in CHC.
23. Girelli D, Pasino M, Goodnough JB, et al.: Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009, 51:845-852.
24. Fujita N, Sugimoto R, Motonishi S, et al.: Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 2008, 49:702-710.
25. Nishina S, Hino K, Korenaga M, et al.: Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008, 134:226-238.
26. Miura K, Taura K, Kodama Y, et al.: Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008, 48:1420-1429. This article describes one mechanism whereby HCV suppresses hepatic hepcidin expression.
27. Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al.: STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007, 109:353-358.
28. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
29. Mleczko-Sanecka K, Casanovas G, Ragab A, et al.: SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood 2010, 115:2657-2665.
30. Kautz L, Meynard D, Monnier A, et al.: Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008, 112:1503-1509.
31. Valenti L, Guido M, Dongiovanni P, et al.: Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. Dig Liver Dis 2009, 41:e17-e20.
32. Lin TJ, Liao LY, Lin CL, et al.: Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C. Hepatogastroenterology 2008, 55:1412-1415.
33. Lambrecht R, Naishadham D, Sterling R, et al.: Relationship of iron [Fe] and HFE genetic variations to progression and outcomes of advanced chronic hepatitis C in the HALT-C Trial. Hepatology 2009, 50:1050A.
34. Ladero JM, Lopez-Alonso G, Devesa MJ, et al.: Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C. Rev Esp Enferm Dig 2009, 101:31-40.
35. Ferrara F, Ventura P, Vegetti A, et al.: Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009, 104:605-616.
36. Desai TK, Jamil LH, Balasubramaniam M, et al.: Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008, 53:815-822. This article provides the definitive meta-analysis establishing that iron reduction significantly improves SVR achieved by IFN alone.
37. Gentile I, Viola C, Paesano L, et al.: Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009, 24:190-196.
38. Rossini A, Contessi G, Liali C, et al.: Efficacy of iron depletion and antiviral therapy in patients with porphyria cutanea tarda and hepatitis C. Hepatology 2004, 40:320A.
39. Tanaka N, Horiuchi A, Yamaura T, et al.: Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. J Gastroenterol 2007, 42:49-55. This article is a demonstration of tolerability of iron reduction by therapeutic phlebotomy even in patients with cirrhosis.
40. Sumida Y, Kanemasa K, Fukumoto K, et al.: Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized, controlled trial on 40 Japanese patients. Intern Med 2007, 46:637-642.
41. Sartori M, Andorno S, Rossini A, et al.: Phlebotomy improves histology in chronic hepatitis C males with mild iron overload. World J Gastroenterol 2010, 16:596-602.
42. Taher AT, Musallam KM, Khalife M, Barada K: Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol 2009, 88:1033-1034.
43. Di Marco V, Capra M, Gagliardotto F, et al.: Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008, 93:1243-1246.
44. Nahon P, Sutton A, Rufat P, et al.: Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008, 134:102-110.
45. Kato J, Miyanishi K, Kobune M, et al.: Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007, 42:830-836. This article describes an important long-term study suggesting benefits of sustained iron reduction, albeit not a prospective, randomized, controlled trial.
46. Van Thiel DH, Friedlander L, Molloy PJ, et al.: Retreatment of hepatitis C interferon nonresponders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996, 43:1557-1561.
47. Fong TL, Han SH, Tsai NC, et al.: A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alphainterferon in patients with chronic hepatitis C. J Hepatol 1998, 28:369-374.
48. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al.: Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000, 32:135-138.
49. Fontana RJ, Israel J, Leclair P et al.: Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000, 31:730-736.
50. Fargion S, Fracanzani AL, Rossini A, et al.: Iron reduction and sustained response to interferon a therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002, 97:1204-1210.
51. Carlo C, Daniela P, Giancarlo C: Iron depletion and response to interferon in chronic hepatitis C. Hepatogastroenterology 2003, 50 (53):1467-1471.